Replies to post #432749 on Amarin Corp Plc (AMRN)

[Whalatane]

Well CBB. you always wanted a BP owner .
Here's what NVS has achieved with Inclisiran ( brand name Leqvio ) that they bt from Denner when he controlled MDCO

Leqvio® continued steady trajectory, delivering +114% cc FY growth
US: Growth outpacing advanced lipid-lowering market1,2
• 3,230 health systems, representing 68% of aLLT market volume, have ordered Leqvio®, with depth increasing +42% vs. PY
• Demand growth in all channels (ASOCs, hospitals, outpatient groups)
Ex-US: Robust growth in all markets
• Leqvionowregisteredin>100countries
• China out-of-pocket growth makes it the top-ranked market ex-US
Multiple Ph3 studies expected to be presented in 2025
• V-MONO:Superiority of Leqviovs.both placebo and ezetimibe inLDL-Creduction3
• V-INCEPTION:First study evaluating the effectiveness of Leqvio initiated in
real-world ASCVD population with ACS = 5 weeks prior to study screening
• ORION-13:Evaluating Leqvio in adolescents with HoFH, first completed study in pediatric program
Constant currencies (cc) is a non-IFRS measure. An explanation can be found on page 47 of the Condensed Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. Novartis obtained global rights to develop, manufacture, and commercialize Leqvio under license / collaboration agreement with Alnylam Pharmaceuticals.
Sales evolution
USD m, % cc
FY USD 0.8bn +114% cc

Note they are doing real world studies with ACS less than 5 wks prior to screening .
At the time a lot pf people thought NVS over paid for Inclisiran ( Leqvivo ) ...amazing what a great BP can do when they get behind a drug

Kiwi